NCT05618314View on ClinicalTrials.gov

Study of AT-527 in Subjects With Normal and Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

June 15, 2024

Study Completion Date

June 15, 2024

Conditions
Healthy VolunteerRenal Impairment
Interventions
DRUG

AT-527

single dose AT-527

DRUG

AT-527

Single dose of AT-527 pre- and post-dialysis

DRUG

AT-527 and Probenecid

Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19

Trial Locations (1)

Unknown

Atea Study Site, Québec

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT05618314 - Study of AT-527 in Subjects With Normal and Impaired Renal Function | Biotech Hunter | Biotech Hunter